BerGenBio AS Initiates Preclinical Development of Novel AXL Inhibitor BGB324
10/31/2011 7:03:11 AM
BERGEN, Norway--(BUSINESS WIRE)--BerGenBio AS, an emerging oncology biopharma, today announced it has initiated preclinical development of its proprietary lead compound, BGB324. This compound will be a first-in-class inhibitor of AXL kinase.
comments powered by